Most Pancreatic Cancer Resections are R1 Resections

By I. Esposito, J. Kleeff, F. Bergmann, C. Reiser, E. Herpel, H. Friess, P. Schirmacher, M. Büchler. Annals of Surgical Oncology, 2008

641 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/55d4f4cc1255c43b5a442696b55264e94cd9a3b9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Bassi
2. C. Dervenis
3. S. Gillen
4. C. Yeo
5. J. Kleeff
6. K. Lillemoe
7. T. Schuster
8. D. Gouma

Citations in the corpus

• Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages (2010, background): “The relatively high percentage of PDAC patients presenting with non-metastatic but ‘‘locally advanced’’ disease as well as the large number of microscopic incomplete resections [11,13] should provide a strong rationale for a neoadjuvant approach.”
• Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). (2014, background): “The aforementioned advice takes into account, to some extent, the results of several studies showing that when the European R1 definition is applied, the rate for positive resection margins is usually >70%, with an impact on survival analysis in retrospective and prospective studies.(55,56) Most of ”